Hologic (NASDAQ:HOLX) CEO Stephen Macmillan purchased 38,600 shares of the stock on the open market in a transaction dated Tuesday, February 11th. The stock was purchased at an average price of $21.58 per share, with a total value of $832,988.00. Following the acquisition, the chief executive officer now directly owns 237,500 shares of the company’s stock, valued at approximately $5,125,250. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
HOLX has been the subject of a number of recent research reports. Analysts at Cantor Fitzgerald reiterated a “buy” rating on shares of Hologic in a research note on Tuesday, February 4th. They now have a $21.00 price target on the stock. Separately, analysts at ISI Group reiterated a “buy” rating on shares of Hologic in a research note on Tuesday, February 4th. They now have a $24.50 price target on the stock. Finally, analysts at ISI Group downgraded shares of Hologic from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 22nd. Three investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and four have given a buy rating to the company. Hologic has an average rating of “Hold” and a consensus target price of $21.97.
Shares of Hologic (NASDAQ:HOLX) opened at 21.41 on Thursday. Hologic has a 52-week low of $18.46 and a 52-week high of $23.24. The stock has a 50-day moving average of $21.65 and a 200-day moving average of $21.82. The company’s market cap is $5.839 billion.
Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, February 3rd. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.03. The company had revenue of $612.40 million for the quarter, compared to the consensus estimate of $609.65 million. During the same quarter in the previous year, the company posted $0.38 earnings per share. The company’s revenue for the quarter was down 3.0% on a year-over-year basis. Analysts expect that Hologic will post $1.37 EPS for the current fiscal year.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products to serving the healthcare needs of women.
Receive News & Ratings for Hologic Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.